Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rebiotix, Inc.

http://www.rebiotix.com/

Latest From Rebiotix, Inc.

Ferring Chief Muses On Moment Of Truth For Microbiome Therapy

When the Swiss company files RBX2660 in the US later this year to reduce recurrences of Clostridioides difficile infection, it will be the first time any firm has tried to get a non-antibiotic product approved to address an infectious disease. Ferring president Per Falk tells Scrip about the 35-year journey to get to this stage and why standardization is key when it comes to microbiome-based therapy.

Infectious Diseases Leadership

Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line

The promise of microbiome-based therapeutics to treat a variety of diseases has become a hot topic and the first to get to market will be targeting Clostridioides difficile infection. Ferring and its subsidiary Rebiotix are in pole position.

Infectious Diseases Clinical Trials

Seres Aims To File C. Diff Microbiome Drug On Single Pivotal Trial

Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.

Clinical Trials Drug Approval Standards

Ferring Hails World First Positive Phase III Data For Microbiome Product

Preliminary efficacy findings from an ongoing pivotal study of Ferring's RBX2660 showed that the first-in-class microbiota-based therapy helped restore the gut microbiome and break the cycle of recurrence of C diff. infection.

Infectious Diseases Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register